Table 3 Clinicopathologic features of patients diagnosed with colorectal liver metastases showing high and low Smad ubiquitination regulatory factor 2 (Smurf2) expression.

Age at primary surgery (years),

Median (range)

68 (46–84)

69 (50–79)

Gender, Male/Female

32/17

12/5

Site of tumor, Colon/Rectum

31/18

9/8

Site of tumor, Right/Left/Rectum

15/16/18

4/5/8

Degree of differentiation,

tub, pap/por, muc

47/2

15/2

Ly, 0–1/2–3

40 / 9

15 / 2

V, 0–1/2–3

24/25

7/10

T stage (8^th edition), 1/2/3/4

0/1/25/23

1/1/9/6

Lymph node metastasis, + / − 

29/20

10/7

CEA before hepatectomy,

median (range)

50.7 ± 170.0

947.2 ± 288.6

CA19-9, median (range)

129.9 ± 497.7

1825.8 ± 845.0

KRAS mutation, Wild/Mutant

9/4

9/7

Adjuvant chemotherapy, + / − 

36/13

13/4

Interval to liver metastasis (months), mean ± SD

5.6 ± 1.5

5.3 ± 2.6

Timing of metastasis,

Synchronous/metachronous

29/20

10/7

Number of liver metastatic tumors, mean ± SD

3.0 ± 0.4

2.6 ± 0.7

Number of liver metastatic tumors, Solitary/Multiple

17/32

6/11

Size of liver metastatic tumors (cm), mean ± SD

3.6 ± 0.4

4.1 ± 0.6

Site of liver metastasis,

Unilateral/Bilateral

17/14

20/15

Hepatectomy, Minor/Major

45/4

11/6

H factor, H1/H2/H3

33/15/1

10/7/0

Extrahepatic metastases, + / − 

9/40

3/14

Resection margin, R0/R1/R2

27/14/8

8/6/3

Adjuvant chemotherapy after hepatectomy, + / − 

36/13

13/4

Recurrence after hepatectomy (all organs), + / − 

38/11

16/1

Intrahepatic recurrence after hepatectomy, + / − 

Number of tumors, mean ± SD

26/23

2.4 ± 0.5

10/7

3.8 ± 0.8

Recurrence in multiple organs, + / − 

6/43

15/2

Repeat resection (all organs), + / − 

24/14

6/10

Repeat hepatectomy, + / − 

13/13

2/8